Eisai

Healthcare
SMEStreet Edit DeskMarch 6, 2023
0
FDA Accepts Eisai’s Filing of a Supplemental Biologics License
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb)…
Read More »
IoT & AI
SMEStreet Edit DeskNovember 4, 2021
0
Eisai Presents New Data from Lecanemab Phase 2B Study
For Early Alzheimer's Disease in Late-Breakers and Pipeline Updates at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Read More »